Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression
Open Access
- 25 July 2014
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (4) , 1-14
Abstract
Introduction: Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear. Methods: Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E2 (PGE2) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on tumor growth. Results: Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with COX-2-overexpressing breast cancer cells. PGE2 released by cancer cells upregulates IDO expression in fibroblasts through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely, fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors inhibit tumor growth in vivo. Conclusion: Integration of metabolomics and molecular and pathological approaches reveals the interplay between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival.Keywords
This publication has 40 references indexed in Scilit:
- Molecular characterization of the tumor microenvironment in breast cancerCancer Cell, 2004
- The role of COX-2 inhibition in breast cancer treatment and preventionSeminars in Oncology, 2004
- Reconstruction of functionally normal and malignant human breast tissues in miceProceedings of the National Academy of Sciences, 2004
- Role of prostaglandin E 2 -dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progressionProceedings of the National Academy of Sciences, 2003
- Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-DioxygenaseJournal of Experimental Medicine, 2002
- Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.2002
- Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.2000
- The role of cyclooxygenases in inflammation, cancer, and developmentOncogene, 1999
- Prospective Study of Regular Aspirin Use and the Risk of Breast CancerJNCI: Journal of the National Cancer Institute, 1996
- Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients.Proceedings of the National Academy of Sciences, 1986